<DOC>
	<DOCNO>NCT02540356</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability BAX69 monotherapy give either intraperitoneal ( IP ) infusion ( Single-Route Arm ) ; IP infusion intravenous ( IV ) infusion ( IV+IP ) ( Double-Route Arm ) , determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) Arm separately , subject refractory ovarian cancer recurrent malignant ascites . In Arms , plasma pharmacokinetics ( PK ) BAX69 characterize , pharmacodynamics ( PD ) marker explore plasma ascites . Two expansion cohort assess tolerability RP2D explore clinical sign efficacy .</brief_summary>
	<brief_title>Phase 1/2a Two-Arm Dose-Escalation Study BAX69 Subjects With Malignant Ascites Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Provision sign informed consent 2 . Female participant nonchildbearing potential , ≥18 year age 3 . Anticipated life expectancy &gt; 3 month time screen 4 . Metastatic ovarian epithelial cancer platinumresistant , good option available investigator 's opinion 5 . Recurrent symptomatic malignant ascites require 2 paracentesis maximum 30day interval prior screen 6 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 2 7 . Adequate hematological function , define : Platelet count ≥100,000/μL Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) &lt; 1.5 time upper limit normal ( ULN ) Absolute neutrophil count ≥1,000/μL Hemoglobin ≥9 g/dL , without need transfusion 2 week prior screen 8 . Adequate renal function , define serum creatinine ≤2.0 time ULN creatinine clearance &gt; 50 mL/min eGFR &gt; 50 mL/min/1.73 m^2 9 . Adequate liver function , define : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 time ULN participant without liver metastasis , ≤5 time ULN presence liver metastases Bilirubin ≤2.0 time ULN , unless participant know Gilbert 's syndrome 10 . Adequate venous access 11 . Participant willing able comply requirement protocol 1 . Known central nervous system metastases 2 . Prior malignancy within past 3 year , exception curatively treat basal squamous cell carcinoma skin , ductal carcinoma situ breast , situ cervical carcinoma , superficial bladder cancer 3 . Participants indwell drain intraperitoneal catheter 4 . Residual AEs &gt; Grade 2 previous treatment 5 . Myocardial infarction within 6 month prior C1D1 , and/or prior diagnosis congestive heart failure ( New York Heart Association Class III IV ) , unstable angina , unstable cardiac arrhythmia require medication ; and/or participant risk polymorphic ventricular tachycardia ( eg , hypokalemia , family history long QT syndrome ) 6 . Uncontrolled hypertension define systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirm upon repeat measure 7 . Left ventricular ejection fraction &lt; 40 % determine echocardiogram ( ECHO ) perform screen within 90 day prior C1D1 8 . QT/QTc interval &gt; 450 msec , C1D1 treatment administration , determine screen ECG 9 . Received antitumor therapy ( chemotherapy , radiotherapy , retinoid therapy , hormonal therapy ) within 4 week ( less 28 day ) prior C1D1 ; antibody therapy , molecular target therapy within 5 halflives prior C1D1 10 . Major surgery within 4 week ( less 28 day ) prior C1D1 11 . Active joint inflammation immune disorder involve joint ( osteoarthritis exclusionary ) 12 . Active infection involve IV antibiotic within 2 week prior C1D1 13 . Positive serology test hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , active tuberculosis 14 . Positive serology test human immunodeficiency virus ( HIV ) type 1 2 , know history immunodeficiency disease 15 . Albumin &lt; 3g/dL total protein &lt; 6g/dL 16 . Participant received live vaccine within 2 week ( less 14 day ) prior C1D1 17 . Known hypersensitivity component recombinant protein production Chinese Hamster Ovary ( CHO ) cell 18 . Exposure investigational product investigational device another clinical study within 4 week ( less 28 day ) prior screen , schedule participate another clinical study involve investigational product device course study 19 . Any disorder disease , clinically significant abnormality laboratory clinical test ( ) ( eg , blood test ECG ) , medical judgment investigator may impede participant 's participation study , pose increase risk participant , and/or confound result study 20 . Participant family member employee investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>